What the approval means
Zepbound (tirzepatide) is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity. The FDA announced the approval in December 2024. Tirzepatide acts on both GIP and GLP-1 receptors.
This is a specific indication, not permission to treat every sleep problem with a GLP-1 medicine. Snoring alone does not establish obstructive sleep apnea (OSA), and the indication does not cover central sleep apnea. Keep using prescribed positive airway pressure (PAP), including CPAP, unless your sleep clinician changes the plan.
Symptoms worth discussing with a clinician
In OSA, the upper airway repeatedly narrows or closes during sleep. Symptoms can include loud snoring, witnessed breathing pauses, waking up gasping, daytime sleepiness, morning headaches, and difficulty concentrating. Obesity is an important risk factor, but people without obesity can also have OSA.
If you or a partner notices these patterns, ask about a sleep evaluation. Do not use weight loss, a quieter night, or a consumer sleep score as a substitute for diagnosis. A sleep clinician determines which testing and treatment are appropriate.
What SURMOUNT-OSA actually found
The primary SURMOUNT-OSA publication describes two randomized, placebo-controlled trials lasting 52 weeks, not 72 weeks. Together they enrolled 469 adults with obesity and moderate-to-severe OSA, without diabetes. Participants received tirzepatide or placebo alongside lifestyle counseling.
The apnea-hypopnea index (AHI) counts breathing pauses and shallow-breathing events per hour of sleep. A lower AHI means fewer such events; it does not by itself describe every symptom or determine whether someone should stop PAP.
| Trial population | Average AHI change with tirzepatide | Average AHI change with placebo |
|---|---|---|
| Trial 1: 234 adults unable or unwilling to use PAP | 25.3 fewer events per hour | 5.3 fewer events per hour |
| Trial 2: 235 adults already using PAP | 29.3 fewer events per hour | 5.5 fewer events per hour |
These are the published treatment-regimen estimates at week 52. Average weight reduction in the tirzepatide groups was 17.7% in trial 1 and 19.6% in trial 2, compared with 1.6% and 2.3% with placebo. These trial averages are not promised outcomes for an individual.
More participants receiving tirzepatide met the study's combined endpoint of either an AHI below 5, or mild OSA with a low sleepiness score. That combined endpoint must not be described as everyone achieving complete remission. The studies also found improvements in hypoxic burden, blood pressure, and a marker of inflammation, but they were not designed to establish long-term cardiovascular outcomes.
Eli Lilly funded the trials and participated in their design, analysis, and reporting. People without obesity and those with central or mixed sleep apnea were excluded, so the results should not be generalized to those groups.
Zepbound and CPAP are not interchangeable
PAP supports breathing during sleep. Medication-related changes in weight and OSA develop over time, and some people continue to need both treatments.
The PAP trial was not designed to determine whether tirzepatide improves PAP adherence or allows patients to discontinue it. Participants planned to continue PAP during the study. The published breathing measurements do not establish a safe home schedule for reducing CPAP use.
If you have lost weight, your mask no longer fits, or pressure feels uncomfortable, contact the sleep team. Ask whether the treatment data and symptoms warrant repeat sleep testing or an equipment adjustment. There is no fixed percentage of weight loss that gives everyone permission to stop treatment.
Wegovy research is a different kind of evidence
Wegovy (semaglutide) should not be described as having the same OSA evidence as Zepbound. In its June 2026 report of exploratory SELECT analyses, Novo Nordisk described fewer newly reported OSA cases with semaglutide injection 2.4 mg than placebo in adults with overweight or obesity and established cardiovascular disease.
Among participants without reported OSA at baseline, there were 30 new cases in the semaglutide group and 65 in the placebo group. The reported hazard ratio was 0.48, with a 95% confidence interval of 0.31 to 0.74.
There are important limits:
- This was a post hoc analysis, not a dedicated trial designed to test treatment of established OSA.
- Baseline OSA was identified by questionnaire; new cases were captured through adverse-event reporting, not scheduled sleep studies for every participant.
- The manufacturer described the analyses as exploratory and hypothesis-generating. Semaglutide is not approved to treat OSA.
These findings do not show that one-third of Wegovy users had their sleep apnea cured. They also do not justify switching treatments or stopping PAP. Weight loss may help OSA, but a measured improvement in one study is not proof of a separate, weight-independent effect on the airway.
Dosing and safety belong in the prescribing visit
The US Zepbound prescribing information lists OSA maintenance doses of 10 mg or 15 mg once weekly. The labeled starting dose is 2.5 mg weekly for four weeks, with increases in 2.5 mg increments after at least four weeks at the current dose. Response and tolerability guide maintenance selection.
This summarizes the FDA-approved titration schedule, not instructions to change your treatment. Your prescriber determines your actual dose. Do not adjust it without consulting them. A higher number is not a reason to accelerate escalation or push through significant side effects.
Discuss these issues before treatment:
- Personal or family history of medullary thyroid carcinoma, MEN 2, or a serious allergic reaction to tirzepatide. These are contraindications in the label.
- Severe stomach-emptying problems, prior pancreatic or gallbladder problems, and persistent vomiting or dehydration.
- Insulin or sulfonylurea use, which can increase low-blood-sugar risk.
- Pregnancy plans and contraception. Tirzepatide has specific precautions for oral contraceptives; review them with your prescriber.
- Any planned anesthesia or deep sedation. Tell the procedure team about the medication and follow their instructions.
Nausea, diarrhea, vomiting, constipation, and abdominal discomfort are among the common adverse effects. Severe or persistent abdominal pain, inability to keep fluids down, or signs of a serious allergic reaction need prompt medical attention rather than waiting for the next routine sleep appointment.
Prepare for the sleep and prescribing appointments
Bring your sleep-study report, current PAP settings and usage information, medication list, and a description of daytime symptoms. Useful questions include:
- Does my sleep study confirm moderate-to-severe OSA, and do I meet the labeled treatment criteria?
- What should I continue using while medication takes effect?
- Which symptoms or side effects should prompt an earlier call?
- When would repeat testing or PAP adjustment be appropriate?
- What documentation does my insurance require for this indication?
An OSA indication does not guarantee coverage; ask your plan about authorization and out-of-pocket costs. A wedge pillow or white-noise machine is not a replacement for prescribed OSA treatment.
For other sleep concerns, see our GLP-1 and sleep guide. Persistent daytime fatigue deserves assessment even if your weight or snoring has improved.
This article is general information, not an individual treatment plan. Do not stop CPAP or change medication doses without guidance from your treating clinicians.
